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After the National Lung Screening Trial (NLST)1
demonstrated improved lung cancer mortality almost
a decade ago, hopes have been raised that low-dose
computed tomography could be used to detect lung
cancer in asymptomatic populations and improve out-
comes by reducing the number of people diagnosed
with advanced disease. The publication of the long-
awaited Nederlands-Leuvens Longkanker Screenings
Onderzoek (NELSON) trial last year2 has provided
further evidence of a lung cancer mortality benefit
and has provoked further calls to implement national
population-based screening programmes, but the case
for lung cancer screening remains controversial.
Evidence for the benefits of screening
The National Lung Screening Trial randomised over
53,000 participants, aged between 55 and 74 years
with at least a 30 pack-year smoking history, to three
annual screening rounds with either chest X-ray or low-
dose computed tomography.1 At a median follow-up of
6.5 years, a relative reduction in lung cancermortality of
20% in the low-dose computed tomography arm (247/
100,000 person-years) compared to the chest X-ray arm
(309/100,000 person-years) was found. A total of 320
screens were required to prevent one lung cancer death
(falling to 303 at 12.3 years),3 a figure comparable to
estimates for breast cancer screening.4,5 The National
Lung Screening Trial is also the only screening trial to
have demonstrated an all-causemortality benefit (6.7%,
95% CI 1.2–13.6); however, this finding was no longer
statistically significant in the recently published
extended follow-up (median 12.3 years follow-up).3
Several smaller trials conducted in Europe were not
powered to determine any mortality benefit6–11 and het-
erogeneity in study design has hindered the prospect of
pooling these results. With almost 16,000 participants
followed up for 10 years, the NELSON trial was
published in February 2020 and is the only trial of
low-dose computed tomography screening aside from
the National Lung Screening Trial which was adequately
powered to demonstrate a lung cancer mortality benefit.2
Participants were randomised to either low-dose com-
puted tomography or routine care. Findings were
broadly comparable to the National Lung Screening
Trial, despite the differing comparators (the National
Lung Screening Trial used a chest X-ray as a control),
with a relative reduction in lung cancer mortality of 24%
at 10 years of follow-up (95% CI: 6–39) for men.12
Moreover, 92–133 participants needed to be screened
per round to prevent one lung cancer death.13
NELSON was not powered to detect an improve-
ment in all-cause mortality. Arguably this is an
unrealistic benchmark since it has been estimated
that it would require 80,000 patients to be rando-
mised and followed up for over a decade to demon-
strate all-cause mortality benefits based on improved
lung cancer outcomes alone.14 The NLST and
NELSON studies are summarised in table 1.
Evidence for the harms of screening
Nodules are found in around half of those screened for
lung cancer. The smallest nodules are not associated
with an increased risk of lung cancer compared to
those with no nodules so do not require further assess-
ment.16 The majority of those that require surveillance
or investigation are found to be benign.17 In the
National Lung Screening Trial, all but the smallest
nodules were considered positive, resulting in false-
positive results for 23.3% of all low-dose computed
tomography scans performed. Reflecting modern sur-
veillance protocols,18,19 NELSON added an ‘inter-
mediate’ group for low-risk nodules. Almost 10% of
all screens fell into this category and required a further
follow-up screen in 3–4 months. Consequently, false
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positives in NELSON were nominally much lower
overall at 1.2%, although over half of the positive
results were still false positives (56.5%).17
In the National Lung Screening Trial, 0.06% of
the false-positive tests in the low-dose computed
tomography group were associated with a ‘major
complication after an invasive procedure’.1
Complications which may have resulted from screen-
ing are yet to be reported for the NELSON trial.
The National Lung Screening Trial reported that
‘clinically significant’ abnormalities other than lung
cancer were identified in 7.5% of the low-dose com-
puted tomography scans. Incidental findings have
been examined for 1929 participants of NELSON,
129 (6.8%) of whom had findings which required fur-
ther evaluation or could have ‘substantial clinical
implications’. Since only 21 (1.1%) were found to rep-
resent significant findings following further evaluation,
the authors argue that searching for and reporting
incidental findings should not be undertaken in low-
dose computed tomography screening trials.20
A proportion of screen-detected cancers may never
have presented symptomatically (over-diagnosis). At 6
years of follow-up, the National Lung Screening Trial
report 18.5% of cases identified by low-dose computed
tomography were due to over-diagnosis; however, this
figure falls to 3.1% at 12 years. Over-diagnosis of
broncho-alveolar cell carcinomas remained high at
79%.3 These lesions are identifiable as pure ground
glass nodules on low-dose computed tomography
and practice has evolved since the National Lung
Screening Trial so that such cases are now followed
up with surveillance21. 8.9% of screen-detected cancers
in NELSON were attributed to over-diagnosis at 11
years, which the authors argue is likely to diminish if
follow-up was extended further.
Some evidence exists that participation in lung
cancer screening has negative psychological conse-
quences22,23 and false-positive results seem likely to
have some adverse effects on quality of life,24 at least
in the short term. However, such effects seem to
attenuate over time, resulting in no clinically signifi-
cant long-term psychosocial harms.25
Radiation exposure over the three screening rounds
in the National Lung Screening Trial has been esti-
mated at 8 mSv. It is thought that screening could
result in one death due to radiation per 2500 people
screened over a 10- to 20-year period26 and that one
radiation induced major cancer may be expected from
every 108 lung cancers detected through screening.27
Biases and uncertainties
Due to themany biases that can affect screening studies,
some have argued that to be confident a screening
intervention is beneficial, it should demonstrate a reduc-
tion in overall (all-cause) deaths rather than only a
reduced number of lung cancer deaths. It has been
argued that without showing an all-cause mortality
reduction considering disease-specific mortality reduc-
tions alone may mask harms that result from screen-
ing.28,29 Although the National Lung Screening Trial
did show a reduction in all-cause mortality, it has also
been questioned whether a genuine benefit exists since
lung cancer cases and cardiovascular disease identified
by NLST cannot account for the overall reduction in
mortality.29,30 As lung cancer causes a minority of
deaths, even among smokers who meet eligibility cri-
teria for the National Lung Screening Trial, a relative
reduction in lung cancer mortality of 20% would only
equate to an all-cause mortality reduction of at most
0.8%.14
Participants in studies, and indeed, screening pro-
grammes are likely to represent healthier cohorts
within the populations at risk of developing cancer,
with important consequences for outcomes.31 A com-
parison of National Lung Screening Trial participants,
compared to those who would be eligible for lung
cancer screening in the US, suggests that a ‘healthy
volunteer’ effect was evident32 while NELSON partici-
pants have been considered broadly representative of
the wider population.33
It is impossible to know for certain whether the
reduced lung cancer deaths demonstrated in the
National Lung Screening Trial and NELSON would
correspond to real-world improvements in overall mor-
tality. Both studies could have provided more detailed
information on complications resulting from screening
to help make that assessment. If the reported low rates
of complications are taken at face value, it seems likely
that the reduction in lung cancer mortality with screen-
ing would be greater than iatrogenic mortality.
Only eligible participants with screen
detected cancers can benefit
Lung cancer screening relies on the selection of individ-
uals with sufficient risk to justify screening. A signifi-
cant proportion of lung cancer cases, perhaps greater
than 10%, occur in people who have no smoking his-
tory at all,34 and less than one-third of patients with
lung cancer in the United States would have been eli-
gible for screening under the National Lung Screening
Trial protocol.35 Meanwhile, uptake for those who are
eligible to participate in screening trials and pilots has
been modest, at around 30%–60%.2,11,36,37 Therefore,
only a minority of patients who develop lung cancer
could be detected through screening.
For those who do participate and develop lung
cancer, a minority will occur between screening
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rounds. Such ‘interval cancers’, which accounted for
12.8% of cases in NELSON, tend to be faster grow-
ing and more aggressive, with poorer outcomes than
screen-detected cancers.31
Informed decision making
It is now acknowledged that information provided to
potential participants of screening should aim to convey
potential benefits and harms, rather than persuade indi-
viduals to take part.38–40 Evidence from theUS suggests
that information provided by clinicians about screening
is not currently adequate to support informed decision
making.41 Adequate communication should be
embedded into any proposed lung cancer screening pro-
gramme, making use of existing decision aids (see
Figure 1)42,43 and developing high-quality resources to
support patient decision making.44
What is current policy on lung cancer
screening?
Lung cancer screening has been recommended by
the United States Preventative Services Task Force
since 201345,46 and has been reimbursed through
Medicare and Medicaid since 2015.47,48 However,
only about 2% of eligible patients undergo screen-
ing.49 This could be due to the lack of central co-
ordination of screening programmes, but may also
reflect limited interest in screening from eligible
individuals.
In Europe, some have called to prepare for lung
cancer screening, even before the results of NELSON
were published,50–54 while others have cautioned
against anticipating the outcome of formal decision-
making processes.55 Lung cancer screening has
become particularly controversial in England, where
‘pilots’ have been established in several localities tar-
geting high-risk populations56,57 with a commitment
to expand the schemes under the NHS long-term
plan.58 Concerns have been raised that the pilots,
promoted as ‘lung health checks’, do not convey
with sufficient clarity that participants are taking
part in a screening programme59 and that their roll
out has bypassed the UK National Screening
Committee,12 which does not currently recommend
population screening for lung cancer.60
Is it cost-effective?
The National Lung Screening Trial was estimated to
yield one quality-adjusted life year at a cost of
$81,00061 while a more recent analysis estimated
costs between $53,000 and $75,000 per quality-
adjusted life year.62 While these estimates reflect the
high cost of healthcare in the US, a systematic review
found that a UK screening programme is unlikely to
be cost-effective at a threshold of £20,000 per
Figure 1. 1000-person tool for lung cancer screening. The tool illustrates estimated outcomes based on in the National Lung
Screening Trial (NLST). Since the NLST most nodules identified on low-dose computed tomography are followed up using a
surveillance protocol, rather than immediate investigation. To reflect contemporary standards of care, this tool assumes the
Lung-RADS protocol is used to interpret low-dose computed tomography results. A 1000-person tool has not yet been created
to reflect the findings of the NELSON study. Reproduced with permission from the International Agency for Research on Cancer.
Full page infographic available at: https://www.iarc.fr/infographics/benefits-and-harms-of-lung-cancer-screening/
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quality-adjusted life year.63 It is possible that an
updated analysis, drawing on the findings of
NELSON and extended follow-up data from the
National Lung Screening Trial which showed fewer
over-diagnosed cases, would produce lower cost esti-
mates. Screening pilots have produced estimates of
under £10,000 per quality-adjusted life year,11,37 pos-
sibly because of their focus on very high-risk popula-
tions. Due to significant staff shortages, particularly in
radiology, the impact of diverting resources to screen-
ing activities on other diagnostic capacity also needs to
be considered. Several strategies are being investigated
to improve the cost-effectiveness of lung cancer screen-
ing including smoking cessation interventions
embedded within screening programmes and efforts
to determine the optimum interval between screens.
No easy answers
The case for lung cancer screening is not straightfor-
ward. Lung cancer is a significant cause of morbidity,
mortality and health inequality, with a disproportion-
ate impact on deprived populations. Low-dose com-
puted tomography screening in high-risk populations
has been shown to significantly reduce lung cancer
mortality.
Updating cost-effectiveness analyses with the find-
ings of NELSON will help inform further policy
Table 1. Summary of the National Lung Screening Trial and NELSON trial.
NLST NELSONa
Eligibility Aged 55–74 years with 30 pack-year
smoking history, who had not
quit smoking within last 15 years
Male, aged 50–74 years who had
smoked >15 cigarettes a day for
>25 years or >10 cigarettes a
day for >30 years, and had not
quit >10 years ago
Number of randomised participants 53,454 13,195
Setting United States Belgium & Netherlands
Available study follow-up periodsb 12.3 years (median) 10–11 years
Intervention and control 3 rounds of annual LDCT vs. 3
rounds of annual chest X-ray
4 rounds of LDCT (at 0, 1, 3 and 5.5
years) vs. no screening
Classification of test resultsc Negative or positive
Positive: any non-calcified nodule
4 mm
Negative, intermediate or positive
Intermediate: nodules 50–500
mm3
Positive: nodules >500 mm3
Overall false-positive rate (%
of positives)c
23.3% (96.4) 1.2% (56.5)




Relative risk reduction in
lung cancer mortality
20.0%
(95% CI: 8–27; p¼ 0.004)
24.0%
(95% CI: 6–39; p¼ 0.01)
Number needed to screen to
prevent 1 lung cancer deathd
303 (at 12.3 years) 92–133 per round
Over-diagnosis ratee 3.1% (at 12.3 years) 8.9% (at 11 years)
aResults reported for NELSON pertain to male patients only, although a small sample of females were randomised and reported separate to the main
results.
bFollow-up in original National Lung Screening Trial publication was for median 6.5 years, with a maximum duration of follow-up of 7.4 years in each
group; however, subsequent analyses have been published based on additional follow-up.
cAbridged classification of results for NELSON which reflects first round of screening. For full nodule management protocol, see Xu et al.15
dNumber needed to screen based on extended follow-up of 12.3 years. The original NLST trial publication reported number needed to screen of 320
based on initial medial follow-up of 6.5 years.
eThe original National Lung Screening Trial publication reported over-diagnosis of 18.5% at 6 years. Nelson reported over-diagnosis of 19.7% at 10
years, reducing to 8.9% when follow-up was extended to 11 years.
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decisions. Given that most people that develop lung
cancer would either not be eligible for or would have
chosen to attend screening, the likelihood that screen-
ing will benefit only a small proportion of partici-
pants, and the inherently controversial nature of
investigating asymptomatic individuals, mean that
decisions about implementing national screening pro-
grammes for lung cancer are unlikely to be settled
with reference to cost-effectiveness alone.
Critics of screening have correctly asserted that it will
always be much less cost-effective than smoking cessa-
tion interventions.64 We do not find this a coherent
reason to dismiss lung cancer screening, since few inter-
ventions would reach that bar of cost-effectiveness. But
we are also not persuaded that the case for lung cancer
screening should be accepted as on the basis of equity
with other cancers, due to similar performance to exist-
ing cancer screening programmes. Much more evidence
has emerged about the harms and uncertainties of
screening since the first programmes were introduced.
The known harms of lung cancer screening are not triv-
ial and include risks resulting from invasive procedures,
the consequences of over-diagnosis and excess
radiation.
It is precisely because such conundrums are so
hard to unravel that the National Screening
Committee was established to advice on UK screen-
ing policy. The National Screening Committee should
have the opportunity to re-evaluate the evidence on
lung cancer screening and make an assessment based
on evidence from trials, cost-effectiveness and with
reference to the values of potential participants. If
deemed cost-effective and acceptable, a national
screening programme could well form part of an
effective strategy to reduce lung cancer deaths if
implemented alongside adequately resourced meas-
ures to reduce smoking and continued emphasis on
the detection and treatment of symptomatic cancers.
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